FrancophonIA/ELRC3.0 huggingface dataset:
English: Materials needed but not included in the pack: - Reconstitution needles (size 22G, length 1½" (0.7 x 40 mm)) - 0.5 or 1 ml injection syringes (with scale intervals of 0.02 ml or smaller).
Estonian: (0,7 x 40 mm)); - 0,5 või 1 ml süstlad (0,02 ml või väiksemate jaotustega).
English: In pre-clinical studies, severe granulomatous inflammations were found associated with the injection sites.
Estonian: Süstekoha reaktsioonid Prekliinilistes uuringutes täheldati süstekohtades tõsist granulomatoosset põletikku.
English: Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome (SBS).
Estonian: Revestive on näidustatud lühikese soole sündroomi raviks 1-aastastel ja vanematel patsientidel.
English: The reconstituted solution should be administered by subcutaneous injection once daily, alternating sites between 1 of the 4 quadrants of the abdomen.
Estonian: Manustamiskõlblik lahus manustatakse üks kord ööpäevas subkutaanse süstena kõhu piirkonna erinevatesse neljandikesse.
English: - if you have had cancer in the gastrointestinal tract, including liver, gallbladder or bile ducts, and pancreas within the last five years.
Estonian: - kui olete teduglutiidi või selle ravimi mis tahes koostisosade (loetletud lõigus 6) või tetratsükliini ravimjääkide suhtes allergiline; - kui teil on vähk või kui teil kahtlustatakse vähki; - kui teil on viimase viie aasta vältel olnud seedetrakti vähk, sealhulgas maksa-, sapipõie- või sapiteede ja pankreasevähk.
English: In case of recurrent intestinal obstructions, the need for continued Revestive treatment should be reassessed.
Estonian: Kõhunäärmega seotud kõrvaltoimete tekkimisel tuleb ravi jätkamise vajadust Revestive'iga uuesti hinnata.
English: The naturally occurring human glucagon-like peptide-2 (GLP-2) is a peptide secreted by L cells of the intestine which is known to increase intestinal and portal blood flow, inhibit gastric acid secretion, and decrease intestinal motility.
Estonian: See peptiid suurendab soolte ja portaalsüsteemi verevoolu, pärsib maosoolhappe sekretsiooni ja vähendab soolte motoorikat.
English: Gallbladder and bile ducts
Estonian: Sapipõis ja sapiteed
English: Revestive 1.25 mg powder and solvent for solution for injection
Estonian: Revestive 1,25 mg süstelahuse pulber ja lahusti
English: 3.6 Check for air bubbles.
Estonian: 3.6 Veenduge, et süstlas ei oleks õhumulle.
English: Discard the vial and reconstitution needle together into the sharps disposal container.
Estonian: Visake viaal ja lahustamisnõel koos teravate esemete hävitamiseks mõeldud konteinerisse.
English: - Dispose of all needles and syringes in a sharps disposal container.
Estonian: - Kõik nõelad ja süstlad tuleb äraviskamiseks panna teravate esemete hävitamiseks mõeldud konteinerisse.
English: No dose adjustment is necessary for paediatric patients with mild and moderate hepatic impairment based on a study conducted in Child-Pugh grade B adult subjects.
Estonian: Child-Pugh klass B maksakahjustusega täiskasvanutega läbiviidud uuringu kohaselt ei ole kerge ja mõõduka maksakahjustusega lastel vaja annust kohandada.
English: Subsequent faecal occult blood testing should be done annually in children and adolescents while they are receiving Revestive.
Estonian: Seejärel tuleb lastel ja noorukitel ravi ajal Revestive'iga teha väljaheite peitvere analüüs üks kord aastas.
English: Contact your doctor or the emergency unit if you experience severe stomach ache and fever - Intestinal obstruction (blockage of the bowel).
Estonian: Võtke ühendust oma arstiga või pöörduge haigla erakorralise meditsiini osakonda, kui teil tekib tugev kõhuvalu koos palavikuga; - soolesulgus (soole ummistumine).
English: NOTE: Do not use the same area each day for each injection - rotate sites (use upper, lower, and left and right side of your belly) to avoid discomfort.
Estonian: Vahetage järjestikku süstimiskohti (kõhupiirkonna ülemine ja alumine vasakpoolne ja parempoolne osa), et vältida süstimisega seoses tekkida võivat ebamugavust.
English: Reconstituted product Chemical and physical in-use stablility has been demonstrated for 24 hours up to 25°C.
Estonian: Lahustatud ravim Ravimi keemilis-füüsikaline stabiilsus on tõestatud 24 tunni jooksul temperatuuril kuni 25 °C.
English: Keep this medicine out of the sight and reach of children.
Estonian: Kuidas Revestive'i säilitada Hoidke seda ravimit laste eest varjatud ja kättesaamatus kohas.
English: No dose adjustment is necessary for patients with mild and moderate hepatic impairment based on a study conducted in Child-Pugh grade B subjects.
Estonian: Child-Pugh klass B maksakahjustusega uuringus osalejatel läbi viidud uuringu kohaselt ei ole kerge ja mõõduka maksakahjustusega patsientidel vaja annust kohandada.
English: Revestive 5 mg powder and solvent for solution for injection Teduglutide
Estonian: Revestive 5 mg süstelahuse pulber ja lahusti teduglutiid
English: Revestive 5 mg powder and solvent for solution for injection teduglutide
Estonian: Revestive 5 mg süstelahuse pulber ja lahusti Teduglutiid
English: Not known thoracic and mediastinal disorders
Estonian: Lineaarsus/mittelineaarsus
English: Hyperplasia in the gall bladder, hepatic biliary ducts, and pancreatic ducts were observed in subchronic and chronic toxicology studies.
Estonian: Subkroonilise ja korduvtoksilisuse uuringutes täheldati sapipõie, maksasiseste sapiteede ja kõhunäärmejuha hüperplaasiat.
English: Revestive 5 mg powder and solvent for solution for injection
Estonian: Revestive 5 mg süstelahuse pulber ja lahusti
English: Seek immediate medical attention if any of the following side effects occur:
Estonian: Järgmiste kõrvaltoimete tekkimisel pöörduge kohe arsti poole:
English: Reconstituted product Chemical and physical stability has been demonstrated for 3 hours at 25°C.
Estonian: Lahustatud ravim Ravimi keemilis-füüsikaline stabiilsus on tõestatud 3 tunni jooksul temperatuuril kuni 25 °C.
English: In case of pancreatic adverse events, the need for continued Revestive treatment should be reassessed.
Estonian: Korduvate soolesulguse episoodide korral tuleb hinnata ravi jätkamise vajadust Revestive'iga.
English: ), every patient should be assessed for the need of an enhanced surveillance schedule based on the patient characteristics (e.g., age and underlying disease, previous occurrence of polyps etc.).
Estonian: Lisaks sellele, et enne ravi alustamist teduglutiidiga on soovitatav teha kolonoskoopia ja eemaldada kõik polüübid (vt lõik 4.4), tuleb iga patsienti lähtuvalt tema individuaalsetest näitajatest (näiteks vanus ja põhihaigus, varasem polüüpide esinemine) hinnata sagedasema jälgimise vajaduse suhtes.
English: Contact the doctor or the emergency unit if your child experiences severe stomach ache and fever - Intestinal obstruction (blockage of the bowel).
Estonian: Võtke ühendust oma lapse arstiga või pöörduge haigla erakorralise meditsiini osakonda, kui teie lapsel tekib tugev kõhuvalu koos palavikuga; - soolesulgus (soole ummistumine).
English: Your doctor will perform further colonoscopies if you continue treatment with Revestive.
Estonian: Ravi jätkamisel Revestive'iga teeb arst teile ka edaspidi kolonoskoopiaid.
English: - After reconstitution, from a microbiological point of view, the solution should be used immediately.
Estonian: - Pärast manustamiskõlblikuks muutmist tuleb mikrobioloogilise saastatuse vältimiseks lahus kohe ära kasutada.
English: The solution must not be used if it is cloudy or contains particulate matter.
Estonian: Ärge kasutage lahust, kui täheldate, et see on hägune või sisaldab nähtavaid osakesi.
English: An individual assessment whether increased frequency of surveillance is necessary should be performed based on the patient characteristics (e.g., age, underlying disease).
Estonian: Sõltuvalt patsiendi individuaalsetest näitajatest (näiteks vanus, põhihaigus) võib olla vajalik sagedasem kolonoskoopiline kontroll (vt ka lõik 5.1).
English: Other side effects include:
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED
English: Revestive should not be used if a cancer is detected during your colonoscopy.
Estonian: Kui kolonoskoopia käigus avastatakse teil vähk, ei tohi teil Revestive'i kasutada.
English: Cases of cholecystitis, cholangitis, and cholelithiasis have been reported in clinical studies.
Estonian: Kliinilistes uuringutes on teatatud sapipõiepõletiku, sapijuhapõletiku ja sapikivitõve juhtudest.
English: Two (2) subjects were weaned off their parenteral support while on teduglutide.
Estonian: 2 uuringus osalejat vabanesid ravi ajal teduglutiidiga parenteraalsest toitmisest.
English: Your doctor will consider this when prescribing this medicine.
Estonian: Teie arst arvestab sellega, kui ta teile seda ravimit välja kirjutab; - kui teil on neerufunktsiooni kahjustus.
English: One subject was weaned off their parenteral support while on teduglutide.
Estonian: 1 uuringus osaleja vabanes ravi ajal teduglutiidiga parenteraalsest toitmisest.
English: Hepatic impairment
Estonian: Südame paispuudulikk us
English: Intravenous use vial (glass)
Estonian: Intravenoosne Viaal (klaasist) 1 viaal
English: Subcutaneous use vial (glass)
Estonian: Viaal (klaasist) 1 viaal
English: Intravenous use
Estonian: Subkutaanne või intravenoosne
English: The full EPAR for Zoledronic acid medac can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Zoledronic acid medac kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It is not recommended for patients with severe kidney problems.
Estonian: Ravimit ei soovitata raske neeruhaigusega patsientidele.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Zoledronic acid medac on 03 August 2012.
Estonian: Euroopa Komisjon andis ravimi Zoledronic acid medac müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 3. augustil 2012.
English: A risk management plan has been developed to ensure that Zoledronic acid medac is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada ravimi Zoledronic acid medac võimalikult ohutu kasutamine.
English: In addition, the company that markets Zoledronic acid medac will provide a card to inform patients about the risk of osteonecrosis of the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth or loosening of teeth) and to instruct them to contact their doctor if they experience symptoms.
Estonian: Lisaks varustab ravimi Zoledronic acid medac turustaja patsiendid teabekaardiga, milles neid teavitatakse lõualuu osteonekroosi riskist (lõualuude kahjustus, mis võib tekitada valu, suuhaavandeid või hammaste logisemist) ning soovitatakse neil sümptomite ilmnemisel arsti poole pöörduda.
English: It is available as a 4mg/100ml solution for infusion (drip into a vein) and as a 4mg/5ml concentrate for solution for infusion.
Estonian: Seda turustatakse infusioonilahusena (veeni tilgutatav lahus) 4 mg/100 ml või infusioonilahuse kontsentraadina 4 mg/5 ml.
English: What measures are being taken to ensure the safe and effective use of Zoledronic acid medac?
Estonian: Mis meetmed võetakse, et tagada ravimi Zoledronic acid medac ohutu ja efektiivne kasutamine?
English: The CHMP concluded that, in accordance with EU requirements, Zoledronic acid medac has been shown to have comparable quality and to be bioequivalent to Zometa.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Zoledronic acid medac võrdväärne kvaliteet ja bioekvivalentsus ravimiga Zometa.
English: Because Zoledronic acid medac is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Zoledronic acid medac on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: No additional studies were needed as Zoledronic acid medac is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Zometa.
Estonian: Lisauuringuid ei olnud vaja, sest Zoledronic acid medac on infusioonina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Zometa.
English: The usual dose of Zoledronic acid medac is one infusion of 4 mg over at least 15 minutes.
Estonian: Ravimi Zoledronic acid medac tavaannus on 4 mg, mida manustatakse ühe infusioonina vähemalt 15 minuti jooksul.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zoledronic acid medac.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For more information about treatment with Zoledronic acid medac, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Zoledronic acid medac toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zoledronic acid medac, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati ravimi Zoledronic acid medac omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: This means that Zoledronic acid medac is similar to a ‘reference medicine' already authorised in the European Union (EU) called Zometa.
Estonian: See tähendab, et ravim Zoledronic acid medac on sarnane võrdlusravimiga Zometa, millel juba on Euroopa Liidus müügiluba.
English: Zoledronic acid medac can be used to prevent bone complications in adults with advanced cancer that is affecting the bone.
Estonian: Ravimit Zoledronic acid medac kasutatakse luutüsistuste ennetamiseks patsientidel, kellel on kaugelearenenud vähk, mis kahjustab luukude.
English: The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases.
Estonian: Luukoe hävimist vähendades muudab ravim luud murdudele vastupidavamaks, mis aitab ennetada luumurdude teket luumetastaasidega vähipatsientidel.
English: Zoledronic acid medac must only be used by a doctor who has experience in the use of this type of medicine given into a vein.
Estonian: Ravimit Zoledronic acid medac tohib patsiendile manustada üksnes seda tüüpi veenisiseste ravimite kasutamises kogenud arst.
English: By preventing the breakdown of bones, Zoledronic acid medac also helps to reduce the amount of calcium released into the blood.
Estonian: Luukoe lagunemist peatades aitab Zoledronic acid medac vähendada verre eralduva kaltsiumi kogust.
English: The Committee recommended that Zoledronic acid medac be given marketing authorisation.
Estonian: Komitee soovitas anda ravimi Zoledronic acid medac müügiloa.
English: This is a summary of the European public assessment report (EPAR) for Zoledronic acid medac.
Estonian: See on ravimi Zoledronic acid medac Euroopa avaliku hindamisaruande kokkuvõte.
English: Zoledronic acid medac can also be used to treat the hypercalcaemia caused by tumours.
Estonian: Ravimit Zoledronic acid medac tohib kasutada ka kasvajast põhjustatud hüperkaltseemia raviks.
English: Other information about Zoledronic acid medac
Estonian: Muu teave ravimi Zoledronic acid medac kohta
English: When used to prevent bone complications, the infusion can be repeated every three to four weeks, and patients should also take supplements of calcium and vitamin D. A lower dose is recommended for patients with bone metastases (when cancer has spread to the bone) if they have mild to moderate problems with their kidneys.
Estonian: Kui ravimit kasutatakse luutüsistuste ennetamiseks, tohib infusiooni korrata iga 3-4 nädala tagant ning patsiendid peavad lisaks võtma kaltsiumi ja D-vitamiini.
English: Zoledronic acid medac is a ‘generic medicine'.
Estonian: Zoledronic acid medac on geneeriline ravim.
English: Zoledronic acid medac is a medicine that contains the active substance zoledronic acid.
Estonian: Zoledronic acid medac on ravim, mis sisaldab toimeainena soledroonhapet.
English: It stops the action of the osteoclasts, the cells in the body that are involved in breaking down the bone tissue.
Estonian: Toimeaine pärsib osteoklastide ehk luukoe lagundamises osalevate rakkude aktiivsust, mis vähendab luukoe hävimist.
English: What is Zoledronic acid medac?
Estonian: Mis on Zoledronic acid medac?
English: Why has Zoledronic acid medac been approved?
Estonian: Miks Zoledronic acid medac heaks kiideti?
English: The active substance in Zoledronic acid medac, zoledronic acid, is a bisphosphonate.
Estonian: Ravimi Zoledronic acid medac toimeaine soledroonhape on bisfosfonaat.
English: How does Zoledronic acid medac work?
Estonian: Kuidas Zoledronic acid medac toimib?
English: Zoledronic acid medac zoledronic acid
Estonian: Zoledronic acid medac soledroonhape
English: How has Zoledronic acid medac been studied?
Estonian: Kuidas ravimit Zoledronic acid medac uuriti?
English: How is Zoledronic acid medac used?
Estonian: Kuidas ravimit Zoledronic acid medac kasutatakse?
English: What is Zoledronic acid medac used for?
Estonian: Milleks ravimit Zoledronic acid medac kasutatakse?
English: It is taken once a day, consistently either in the morning or in the evening.
Estonian: Seda manustatakse üks kord ööpäevas, alati kas hommikul või õhtul.
English: Further information on Sprycel can be found on the Agency's website ema.europa.eu/medicines/human/EPAR/Sprycel.
Estonian: Lisateave Spryceli kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Sprycel.
English: The dose is then gradually increased until the disease is controlled well enough.
Estonian: Seejärel annust järk-järgult suurendatakse, kuni haigus allub piisavalt ravile.
English: What measures are being taken to ensure the safe and effective use of Sprycel?
Estonian: Mis meetmed võetakse, et tagada Spryceli ohutu ja efektiivne kasutamine?
English: The European Medicines Agency decided that Sprycel's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Spryceli kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Sprycel (dasatinib)
Estonian: Sprycel (dasatiniib)
English: Sprycel received a marketing authorisation valid throughout the European Union on 20 November
Estonian: Sprycel on saanud müügiloa, mis kehtib kogu ELis, 20. novembril 2006.
English: What is Sprycel and what is it used for?
Estonian: Mis on Sprycel ja milleks seda kasutatakse?
English: Other information about Sprycel
Estonian: Muu teave Spryceli kohta
English: The doses for Sprycel tablets and suspension are not the same.
Estonian: Spryceli tablettide ja suspensiooni annused on erinevad.
English: Sprycel is available as tablets (20, 50, 70, 80, 100 and 140 mg) and a powder to make up a suspension (10 mg/ml) to be taken by mouth.
Estonian: Sprycelit turustatakse tablettidena (20, 50, 70, 80, 100 ja 140 mg) ja suukaudse suspensiooni pulbrina (10 mg/ml).
English: Sprycel is also used in children to treat:
Estonian: Sprycelit kasutatakse ka lastel järgmiste seisundite raviks:
English: The most common side effects with Sprycel (seen in more than 1 patient in 10) are infection, suppression of the bone marrow (decreasing numbers of blood cells), headache, haemorrhage (bleeding), pleural effusion (fluid around the lungs), dyspnoea (difficulty breathing), diarrhoea, vomiting, nausea (feeling sick), abdominal pain (belly ache), skin rash, musculoskeletal pain, tiredness, swelling in the legs and arms and in the face, fever.
Estonian: Spryceli kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on infektsioon, luuüdi supressioon (vererakkude vähenemine), peavalu, hemorraagia (verejooks), pleuraefusioon (vedelik kopsude ümber), düspnoe (raskendatud hingamine), kõhulahtisus, oksendamine, iiveldus, kõhuvalu, nahalööve, luu-lihaskonna valu, väsimus, jäsemete ja näo turse, palavik.
English: Side effects reported with Sprycel are carefully evaluated and any necessary action taken to protect patients.
Estonian: Spryceli kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: What are the risks associated with Sprycel?
Estonian: Mis riskid Spryceliga kaasnevad?
English: None of these studies compared Sprycel with another medicine.
Estonian: Üheski uuringus ei võrreldud Sprycelit ühegi muu ravimiga.
English: As for all medicines, data on the use of Sprycel are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Spryceli kasutamise kohta pidevat järelevalvet.
English: By blocking Bcr-Abl kinase, as well as other kinases, Sprycel helps to reduce the number of leukaemia cells.
Estonian: Blokeerides Bcr-Abl-kinaasi ning samuti muid kinaase, aitab Sprycel vähendada leukeemiarakkude arvu.
English: Treatment is stopped if the medicine no longer controls the condition or if the patient cannot take the medicine because of side effects.
Estonian: Ravi lõpetatakse, kui seisund ei allu enam ravile või kui patsient ei saa ravimit kõrvalnähtude tõttu kasutada.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sprycel have been included in the summary of product characteristics and the package leaflet.
Estonian: Spryceli ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Sprycel is a cancer medicine.
Estonian: Sprycel on vähiravim.
English: For more information about using Sprycel, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Spryceli kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Sprycel is used when other treatments do not work or cause troublesome side effects.
Estonian: Sprycelit kasutatakse, kui muud ravimid ei toimi või tekitavad probleemseid kõrvalnähte.
English: How does Sprycel work?
Estonian: Kuidas Sprycel toimib?
English: Ph+ means that some of the patient's genes have rearranged themselves to form a special chromosome called the Philadelphia chromosome which produces an enzyme, Bcr-Abl kinase that leads to the development of leukaemia.
Estonian: Ph+ tähendab, et teatud geenide ümberkorralduse tõttu on tekkinud eriline kromosoom, mida nimetatakse Philadelphia kromosoomiks ja mis kodeerib leukeemiat põhjustavat ensüümi Bcr-Abl-kinaasi.
English: A response was seen in around 90% of patients who could not use imatinib or it had not worked, and in 94% of newly diagnosed patients.
Estonian: Ravivastus tekkis ligikaudu 90%-l patsientidest, kes ei saanud kasutada imatiniibi või kellel ei olnud tekkinud sellega ravivastust, ning 94%-l esmadiagnoosiga patsientidest.
English: In patients with CML in other phases (accelerated, myeloid blast and lymphoid blast) and in ALL, around 25 to 33% of the patients had complete response.
Estonian: Kroonilise müeloidleukeemia muude faaside (aktseleratsiooni, müeloblastne ja lümfoblastne faas) ja akuutse lümfoblastleukeemia korral oli täieliku ravivastusega patsiente ligikaudu 25-33%.
English: Sprycel is used when other treatments including imatinib (another cancer medicine) do not work or cause troublesome side effects;
Estonian: Sprycelit kasutatakse juhul, kui muud ravimid, sh imatiniib (samuti vähiravim) ei toimi või tekitavad probleemseid kõrvalnähte.
English: Among patients treated with Sprycel and chemotherapy, 66% did not have an unwanted event.
Estonian: Sprycelit ja keemiaravi kasutanud patsientidest 66%-l ei esinenud soovimatuid sündmusi.